<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467597</url>
  </required_header>
  <id_info>
    <org_study_id>RCD-003-05F</org_study_id>
    <nct_id>NCT00467597</nct_id>
  </id_info>
  <brief_title>Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)</brief_title>
  <official_title>Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD)
      patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD
      symptoms, levodopa. In this study, we will test if biochemical devices are equal to the
      clinical rating system in measuring dyskinesias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levodopa induced dyskinesia (LID) is a major problem associated with chronic use of levodopa
      (LD) for symptomatic treatment of Parkinson's disease (PD). LD remains our most potent
      therapy and nearly all PD patients will use it. A substantial portion of them will experience
      LID, with the impact ranging from non-interfering to severely disabling. The objective of
      this study is to develop reliable and sensitive objective measures of LID that will quantify
      muscular control and postural stability in subjects with dyskinesia.

      While the &quot;gold standard&quot; of measuring LID is the subjective RS, we will determine if
      objective biochemical devices will equal the reliability and validity of CRS. We hypothesize
      that force plate technology quantifies postural sway movements best, and pinch-grip will best
      quantify muscle overflow force during voluntary movements.

      We will compare two biomechanical devices and a traditional clinical rating scale (CRS). Once
      biomechanical instrument measures LID in the setting of voluntary muscle activity, the other
      acquires LID data related to postural sway.. A cross-section of LD-treated patients with and
      without clinically apparent dyskinesia will be used to assess the measures.

      32 subjects will be invited to participate, 24 with PD and 8 age-matched controls (likely
      unaffected spouses) without neurologic disease. Of the PD patients 7 will have no clinically
      apparent dyskinesia, 7 will have mild dyskinesia and 7 with moderate to severe dyskinesia
      will be recruited (3 additional subjects are included to account for missing data or
      drop-outs).

      They will comfortably stand with their feet placed in a preset marked stance on the force
      plate either with or without a mental task and pick up a pinch-grip device multiple times.
      Testing will be done in the effective motor &quot;on&quot; and &quot;off&quot; states to establish validity and
      reliability of instrument data, as these states often reflect the usual clinical experience
      of patients. The second method for rating dyskinesia will be the Clinical Rating Scale.
      Subjects will be rated while standing on the force plate during both mental task and
      non-mental task conditions.

      All subjects will undergo this testing. Healthy subjects will undergo this testing three
      times during one visit. Subjects with PD will be admitted overnight, and have seven testing
      periods which will vary in the number of times the procedures will be done. Inpatient
      subjects will also receive 1mg/kg/hr or 1.5mg/kg/hr of intravenous levodopa depending on
      their everyday usage of levodopa or levodopa equivalent medications for 2 hours (9AM - 11AM)
      with carbidopa 25 mg po at 8AM, 10AM and noon to prevent nausea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gaitmat Stance Measurements (AUC)</measure>
    <time_frame>Every 1/2 hour during an 8 hour period.</time_frame>
    <description>Gaitmat stance measurements were measured every half hour throughout an 8 hour period. Area under the curve was computed using the trapezoidal method for root mean squared velocity in the anterior-posterior direction. Each subject's unique baseline was used by computing the mean of the test-retest period measured at 08:00 am.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Dyskinesias</condition>
  <condition>Movement Disorders</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa (delivered intravenously)</intervention_name>
    <description>IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full &quot;on&quot; and &quot;off&quot; levodopa cycle while in the inpatient unit.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's disease patients on Levodopa with or without dyskinesia (abnormal involuntary
        movements caused by levodopa usage).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of probable idiopathic Parkinson's Disease or no neurologic disease
             (no disease for controls only)

          -  At least 21 years of age

          -  Mini Mental Status Exam Score&gt;=25

        Exclusion Criteria:

          -  Evidence of psychosis (hallucinations or delusions) by history

          -  Any unstable medical condition

          -  Currently using dopamine blocking medication

          -  Currently taking anticoagulants or MAO inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Anne Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Portland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <results_first_submitted>October 30, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyskinesia</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Movement Disorders</keyword>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Parkinson's Disease</title>
          <description>Parkinson's disease with and without Levodopa-Induced Dyskinesia (no intervention).</description>
        </group>
        <group group_id="P2">
          <title>Controls</title>
          <description>Non-Parkinson's Disease Controls (no intervention).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PD - No LID</title>
          <description>Parkinson's disease without levodopa-induced dyskinesia</description>
        </group>
        <group group_id="B2">
          <title>PD - Mild LID</title>
          <description>Parkinson's disease with mild to moderate levodopa-induced dyskinesia (mAIMS &lt;= 7)</description>
        </group>
        <group group_id="B3">
          <title>PD - Mod LID</title>
          <description>Parkinson's disease with moderate to severe levodopa-induced dyskinesia (mAIMS &gt; 8)</description>
        </group>
        <group group_id="B4">
          <title>Controls - No PD</title>
          <description>Controls with no Parkinson's disease</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="6.1"/>
                    <measurement group_id="B2" value="62.8" spread="10.6"/>
                    <measurement group_id="B3" value="61.4" spread="6.8"/>
                    <measurement group_id="B4" value="68.3" spread="8.2"/>
                    <measurement group_id="B5" value="64.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="3.1"/>
                    <measurement group_id="B2" value="10.2" spread="5.0"/>
                    <measurement group_id="B3" value="10.5" spread="4.8"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="9.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS (part III)</title>
          <description>Unified Parkinson's Disease Rating Scale - Part III (Motor Section). This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. Higher values on this scale represent a more severe stage of the disease. the total score ranges from 0 to 108, with higher scores representing a more sever stage of the disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="7.9"/>
                    <measurement group_id="B2" value="23.5" spread="12.7"/>
                    <measurement group_id="B3" value="12.0" spread="8.0"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="15.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mAIMS at Screening</title>
          <description>Modified Abnormal Involuntary Movement Rating Scale (mAIMS). This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms) during the finger tapping task, and during the Get-Up and go task (both described below). All body parts are rated separately on this 0 (none) to 4 (severe – markedly impairs activities) scale. Thus, the total score can range from 0 – 28 with 28 indicating the most severe LID.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="1.6" spread="2.4"/>
                    <measurement group_id="B3" value="11.8" spread="3.5"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="3.1" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gaitmat Stance Measurements (AUC)</title>
        <description>Gaitmat stance measurements were measured every half hour throughout an 8 hour period. Area under the curve was computed using the trapezoidal method for root mean squared velocity in the anterior-posterior direction. Each subject's unique baseline was used by computing the mean of the test-retest period measured at 08:00 am.</description>
        <time_frame>Every 1/2 hour during an 8 hour period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PD - No LID</title>
            <description>Parkinson's disease without levodopa-induced dyskinesia</description>
          </group>
          <group group_id="O2">
            <title>PD - Mild LID</title>
            <description>Parkinson's disease with mild to moderate levodopa-induced dyskinesia (mAIMS &lt;= 7)</description>
          </group>
          <group group_id="O3">
            <title>PD - Mod LID</title>
            <description>Parkinson's disease with moderate to severe levodopa-induced dyskinesia (mAIMS &gt; 8)</description>
          </group>
          <group group_id="O4">
            <title>Controls - No PD</title>
            <description>Controls with no Parkinson's disease</description>
          </group>
        </group_list>
        <measure>
          <title>Gaitmat Stance Measurements (AUC)</title>
          <description>Gaitmat stance measurements were measured every half hour throughout an 8 hour period. Area under the curve was computed using the trapezoidal method for root mean squared velocity in the anterior-posterior direction. Each subject's unique baseline was used by computing the mean of the test-retest period measured at 08:00 am.</description>
          <units>Root Mean Square of Velocity*Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="2.1"/>
                    <measurement group_id="O2" value="10.8" spread="12.1"/>
                    <measurement group_id="O3" value="20.9" spread="26.0"/>
                    <measurement group_id="O4" value="2.8" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PD - No LID</title>
          <description>Parkinson's disease without levodopa-induced dyskinesia</description>
        </group>
        <group group_id="E2">
          <title>PD - Mild LID</title>
          <description>Parkinson's disease with mild to moderate levodopa-induced dyskinesia (mAIMS &lt;= 7)</description>
        </group>
        <group group_id="E3">
          <title>PD - Mod LID</title>
          <description>Parkinson's disease with moderate to severe levodopa-induced dyskinesia (mAIMS &gt; 8)</description>
        </group>
        <group group_id="E4">
          <title>Controls - No PD</title>
          <description>Controls with no Parkinson's disease</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Chung, MD</name_or_title>
      <organization>Portland VA Health Care System (PORVAHCS)</organization>
      <phone>503.220.8262 ext 51091</phone>
      <email>CHUNGKA@OHSU.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

